会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • PROCESS FOR THE RECOVERY OF A 'beta'-LACTAM ANTIBIOTIC
    • 恢复β-LACTAM抗生素的方法
    • WO1996023797A1
    • 1996-08-08
    • PCT/NL1996000053
    • 1996-02-01
    • CHEMFERM V.o.F.BOESTEN, Wilhelmus, Hubertus, Joseph
    • CHEMFERM V.o.F.
    • C07D501/12
    • C07D499/00C07D501/00C12P35/00
    • Process for the recovery of a beta -lactam antibiotic from a mixture containing the ammonium salt of the beta -lactam antibiotic and the ammonium salt of the corresponding beta -lactam core by subjecting the mixture to a physical treatment, for instance a treatment of stripping with steam or an inert gas or (steam) distillation at reduced pressure, in which ammonia is released from the ammonium salts that are present and is carried off as such and the precipitate of the beta -lactam antibiotic released is recovered. The mixture for instance is the reaction mixture obtained after an enzymatic acylation reaction in which the beta -lactam antibiotic is prepared from the corresponding beta -lactam core and the corresponding acylation agent. Preferably, the mixture obtained after recovery of the precipitate of the beta -lactam antibiotic is returned to the enzymatic acylation reaction. In such a process essentially no beta -lactam core and beta -lactam antibiotic are lost. Moreover, the enzyme can be re-used many times.
    • 从含有β-内酰胺抗生素的铵盐和相应的β-内酰胺核心的铵盐的混合物中回收β-内酰胺抗生素的方法,通过使混合物进行物理处理,例如用 蒸汽或惰性气体或(蒸汽)减压蒸馏,其中氨从存在并被除去的铵盐中释放出来,并回收释放的β-内酰胺抗生素的沉淀物。 混合物例如是在酶促酰化反应后获得的反应混合物,其中β-内酰胺抗生素由相应的β-内酰胺核心和相应的酰化剂制备。 优选地,将回收β-内酰胺抗生素沉淀物后获得的混合物返回到酶酰化反应。 在这样的过程中,基本上不会失去β-内酰胺核心和β-内酰胺抗生素。 此外,酶可以重复使用多次。
    • 10. 发明申请
    • PROCESS FOR THE PREPARATION OF CEFUROXIME AXETIL IN AN AMORPHOUS FORM
    • 用于制备非晶形态中的CEFUROXIME AXITIL的方法
    • WO99065919A1
    • 1999-12-23
    • PCT/IB1999/000145
    • 1999-01-27
    • C07D501/00C07D501/02C07D501/12
    • C07D501/00
    • A process for preparing cefuroxime axetil in substantially amorphous form comprises forming a mixture of crystalline cefuroxime axetil and at least one pharmaceutically acceptable excipient, and subjecting the mixture to milling for a period of time sufficient to convert the crystalline cefuroxime axetil to substantially amorphous form, i.e., the crystallinity is less than 5 %. The amorphous cefuroxime axetil has a chemical purity of at least 95 %. Desirably, the particles of the milled material are reduced to a size of less than 2 mu m. The amorphous cefuroxime axetil prepared by this method may consist of R isomer, S isomer, or a racemic mixture of the R and S isomers.
    • 制备基本无定形形式的头孢呋辛酯的方法包括形成结晶头孢呋辛酯和至少一种药学上可接受的赋形剂的混合物,并使混合物磨碎一段时间以足以将结晶头孢呋辛酯转变为基本上无定形的形式,即 ,结晶度小于5%。 无定形头孢呋辛酯的化学纯度至少为95%。 理想地,研磨材料的颗粒被还原成小于2μm的尺寸。 通过该方法制备的无定形头孢呋辛酯可由R异构体,S异构体或R和S异构体的外消旋混合物组成。